The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

Reports Q4 revenue $ $3.71M , consensus $5.47M…Bicycle Therapeutics (BCYC) is currently conducting the Phase 2/3 Duravelo-2 registrational ...

Medicenna Therapeutics Corp. shares T.MDNA are trading unchanged at $1.13.

Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothe ...

A GROUNDBREAKING cancer vaccine reversed the disease in nine patients, a study has shown. They remained disease free three ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further ...